(Q40630169)

English

Comparison of meropenem with amikacin plus ceftazidime in the empirical treatment of febrile neutropenia: a prospective randomised multicentre trial in patients without previous prophylactic antibiotics. Meropenem Study Group of Turkey

scientific article published on September 1999

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

22 September 2017

Comparison of meropenem with amikacin plus ceftazidime in the empirical treatment of febrile neutropenia: a prospective randomised multicentre trial in patients without previous prophylactic antibiotics. Meropenem Study Group of Turkey (English)

1 reference

Europe PubMed Central

22 September 2017

multicenter clinical trial

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Akova M

1

1 reference

Europe PubMed Central

22 September 2017

Akan H

2

1 reference

Europe PubMed Central

22 September 2017

Korten V

3

1 reference

Europe PubMed Central

22 September 2017

Biberoğlu K

4

1 reference

Europe PubMed Central

22 September 2017

Hayran M

5

1 reference

Europe PubMed Central

22 September 2017

Unal S

6

1 reference

Europe PubMed Central

22 September 2017

Kars A

7

1 reference

Europe PubMed Central

22 September 2017

Kansu E

8

1 reference

Europe PubMed Central

22 September 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

1 September 1999

1 reference

Europe PubMed Central

22 September 2017

International Journal of Antimicrobial Agents

1 reference

Europe PubMed Central

22 September 2017

13

1 reference

Europe PubMed Central

22 September 2017

15-19

1 reference

Europe PubMed Central

22 September 2017

1

1 reference

Europe PubMed Central

22 September 2017

1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Infectious Diseases Society of America

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900096-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Empirical treatment of febrile neutropenia: evolution of current therapeutic approaches

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900096-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Beta-lactam antibiotic therapy in febrile granulocytopenic patients. A randomized trial comparing cefoperazone plus piperacillin, ceftazidime plus piperacillin, and imipenem alone

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900096-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Monotherapy for fever and neutropenia in cancer patients: a randomized comparison of ceftazidime versus imipenem

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900096-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Equivalent efficacies of meropenem and ceftazidime as empirical monotherapy of febrile neutropenic patients. The Meropenem Study Group of Leuven, London and Nijmegen

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900096-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Re

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900096-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Empiric antibiotic monotherapy with carbapenems in febrile neutropenia: a review

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900096-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Emergence of quinolone-resistant Escherichia coli bacteremia in neutropenic patients with cancer who have received prophylactic norfloxacin.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900096-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0924-8579(99)00096-5

1 reference

Europe PubMed Central

22 September 2017

1 reference

Europe PubMed Central

22 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40630169&oldid=1903801165"